| Table 1. Numbers of retrieved and vitrified oocytes stratified by age | |||||||||||||
| A. Donors | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Age | Nº | Doses of gonadotropins | Nº oocyte retrieval | Nº of oocyte MII | Nº of oocyte GVBD | Nº of oocyte GV | Nº of atretic oocyte | |||||
| DONOR | <21 | 96 | 2087±369 | 17.53±8.95 | 14.18±7.68 | 0.84±1.11 | 1.97±2.74 | 0.50±0.79 | |||||
| 21-25 | 121 | 2062±369 | 19.60±13.10 | 15.80±10.77 | 0.83±1.22 | 2.24±3.29 | 0.50±0.85 | ||||||
| 26-30 | 71 | 2056±434 | 19.75±12.70 | 15.13±9.74 | 0.83±1.11 | 2.85±3.37 | 1.00±2.74 | ||||||
| B. Patients | |||||||||||||
| Group | Age | Nº | Doses of gonadotropins | Nº oocyte retrieval | Nº of oocyte MII | Nº of oocyte GVBD | Nº of oocyte GV | Nº of atretic oocyte | |||||
| PATIENT | <21 | 2 | 2025±250 | 12.00±7.07 | 8.00±.24 | 1.50±0.71 | 2.00±1.41 | 0.50±0.71 | |||||
| 21-25 | 15 | 2133±342 | 17.80±11.92 | 13.60±8.96 | 0.93±1.10 | 2.80±4.74 | 0.47±0.74 | ||||||
| 26-30 | 19 | 2300±156 | 12.79±7.26a | 10.89±6.91 | 0.84±1.07 | 0.79±.92a | 0.26±0.45 | ||||||
| 31-35 | 60 | 2371±558 | 9.60±7.54a | 7.43±6.05a | 0.50±0.89 | 1.33±2.12a | 0.23±0.62 | ||||||
| 36-40 | 192 | 2285±841 | 5.63±5.92a,b,c | 4.54±4.91a,b,c | 0.36±0.70 | 0.53±1.04a,c | 0.17±0.44 | ||||||
| 41-45 | 100 | 2066±807 | 3.46±3.72a,b,c | 2.79±3.15a,b,c | 0.18±0.48a,b | 0.23±0.57a,c | 0.20±0.68 | ||||||
| >45 | 10 | 1800±252 | 1.30±1.25a,b,c | 1.20±1.32a,b,c | 0.00a | 0.00a | 0.10±0.32 | ||||||
| Oocytes vitrified at the MII stage. MII= metaphase II; GVBD= germinal vesicle breakdown; GV= germinal vesicle. The statistical analysis was performed and should be interpreted as follows: (a) statistically different means of the following agegroups 21 - 25 (p<0.05); (b) with 26 - 30 (p<0.05) and (c) with 31 - 35 (p<0.05). | |||||||||||||